3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase EARLY_PHASE1
1
Phase 3
1
Phase 2/3
1
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Breast Neoplasms
12
Carcinoma, Non-Small-Cell Lung
8
Ovarian Neoplasms
6
Fallopian Tube Neoplasms
5
Lung Neoplasms
4
Stomach Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Esophageal Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Inflammatory Breast Neoplasms
2
Head and Neck Neoplasms
2
Carcinoma, Ductal, Breast
2
Adenocarcinoma Of Esophagus
2
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
The Neoadjuvant Therapy
1
Testicular Neoplasms
1
Testicular Germ Cell Tumor
1
Teratoma
1
Stage IIIB or IV Non-Small Cell Lung Cancer
1
Seminoma
1
Recurrence
1
Primary Malignant Neoplasm of Ovary
1
Peripheral Nervous System Diseases
1
Pancreatic Neoplasms
1
Neoplasms, Cystic, Mucinous, and Serous
1
Neoplasm Metastasis
1
Interventions
trametinib
1
fosbretabulin
1
dabrafenib
1
combretastatin
1
cobimetinib
1
Vemurafenib
1
Paclitaxel
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Thyroid Carcinoma, Anaplastic
×
Paclitaxel
×
Clear all
NCT00507429
2014-06-09
FACT
Mateon Therapeutics
Phase 2/3
Terminated
80 enrolled
10 charts